Generic placeholder image

Current Medical Imaging

Editor-in-Chief

ISSN (Print): 1573-4056
ISSN (Online): 1875-6603

Case Report

Atypical Cytotoxic Lesion and Hemorrhagic Involvement of the Corpus Callosum in Severe COVID-19 Infection

Author(s): Angela Guarnizo-Capera, Manuela Gallo Tapias, José David Cardona Ortegón* and Valentina Ferrer Valencia

Volume 20, 2024

Published on: 06 June, 2023

Article ID: e140423215809 Pages: 4

DOI: 10.2174/1573405620666230414110124

open_access

Open Access Journals Promotions 2
Abstract

Introduction/Background: The COVID-19 pandemic has resulted in a large number of deaths and has caused a significant increase in population morbidity. This viral infection has been associated with different neurological symptoms and complications that do not have a clear pathophysiological mechanism and exact implications for these patients.

Case Presentation: A 40-year-old man with COVID-19 and co-infection with Klebsiella pneumoniae KPC presented extensive pulmonary involvement and required comprehensive management in the intensive care unit (ICU). During his hospitalization, he developed neurological symptoms with evidence of involvement of the corpus callosum, which was attributed to the cytotoxic lesion of the corpus callosum (CLOCC). After several months of interdisciplinary management in the ICU, there was a progressive improvement in his general condition, with discharge from the hospital without significant sequelae, with follow-up images showing complete involvement of the corpus callosum due to what was considered an atypical cytotoxic lesion of the corpus callosum.

Conclusion: Imaging features of CLOCCs are known to be temporary, but in the setting of COVID-19, it has not yet been determined if this is true and further studies are needed. Nonetheless, the one-year follow-up of our patient makes us believe that this atypical involvement of the corpus callosum described in severe SARS-CoV-2 infections is not transitory, even if there are no neurologic sequelae.

Keywords: Critical care, COVID-19, Atypical cytotoxic lesion, Corpus callosum, Cytotoxic lesion, Intensive care unit (ICU).

[1]
Geneva S. World Health Organization. Coronavirus disease 2019 (COVID-19) situation report – 110. 2019. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---21-september-2022
[2]
Klironomos S, Tzortzakakis A, Kits A, et al. Nervous system involvement in coronavirus disease 2019: Results from a retrospective consecutive neuroimaging cohort. Radiology 2020; 297(3): E324-34.
[http://dx.doi.org/10.1148/radiol.2020202791] [PMID: 32729812]
[3]
Guerrero JI, Barragán LA, Martínez JD, et al. Central and peripheral nervous system involvement by COVID-19: A systematic review of the pathophysiology, clinical manifestations, neuropathology, neuroimaging, electrophysiology, and cerebrospinal fluid findings. BMC Infect Dis 2021; 21(1): 515.
[http://dx.doi.org/10.1186/s12879-021-06185-6] [PMID: 34078305]
[4]
Rasmussen C, Niculescu I, Patel S, Krishnan A. COVID-19 and involvement of the corpus callosum: Potential effect of the cytokine storm? AJNR Am J Neuroradiol 2020; 41(9): 1625-8.
[http://dx.doi.org/10.3174/ajnr.A6680] [PMID: 32732269]
[5]
Starkey J, Kobayashi N, Numaguchi Y, Moritani T. Cytotoxic lesions of the corpus callosum that show restricted diffusion: Mechanisms, causes, and manifestations. Radiographics 2017; 37(2): 562-76.
[http://dx.doi.org/10.1148/rg.2017160085] [PMID: 28165876]
[6]
Miller AH, Haroon E, Raison CL, Felger JC. Cytokine targets in the brain: Impact on neurotransmitters and neurocircuits. Depress Anxiety 2013; 30(4): 297-306.
[http://dx.doi.org/10.1002/da.22084] [PMID: 23468190]
[7]
Bonavia L, McOwan B, Jackson J. Cytotoxic lesion of the corpus callosum in a case of Q fever. J Clin Neurosci 2022; 104(1): 62-3.
[http://dx.doi.org/10.1016/j.jocn.2022.08.004] [PMID: 35964404]
[8]
Takanashi J. Two newly proposed infectious encephalitis/encephalopathy syndromes. Brain Dev 2009; 31(7): 521-8.
[http://dx.doi.org/10.1016/j.braindev.2009.02.012] [PMID: 19339128]
[9]
Zhu Y, Zheng J, Zhang L, et al. Reversible splenial lesion syndrome associated with encephalitis/encephalopathy presenting with great clinical heterogeneity. BMC Neurol 2016; 16(1): 49.
[http://dx.doi.org/10.1186/s12883-016-0572-9] [PMID: 27089920]
[10]
Tetsuka S. Reversible lesion in the splenium of the corpus callosum. Brain Behav 2019; 9(11): e01440.
[http://dx.doi.org/10.1002/brb3.1440] [PMID: 31588684]
[11]
Coolen T, Lolli V, Sadeghi N, et al. Early postmortem brain MRI findings in COVID-19 non-survivors. Neurology 2020; 95(14): e2016-27.
[http://dx.doi.org/10.1212/WNL.0000000000010116] [PMID: 32546654]
[12]
Kubo M, Kubo K, Kobayashi K, Komiya N. Non-severe COVID-19 complicated by cytotoxic lesions of the corpus callosum (mild encephalitis/encephalopathy with a reversible splenial lesion): A case report and literature review. Int J Infect Dis 2022; 125(1): 1-9.
[http://dx.doi.org/10.1016/j.ijid.2022.09.009] [PMID: 36122669]
[13]
Maeda M, Tsukahara H, Terada H, et al. Reversible splenial lesion with restricted diffusion in a wide spectrum of diseases and conditions. J Neuroradiol 2006; 33(4): 229-36.
[http://dx.doi.org/10.1016/S0150-9861(06)77268-6] [PMID: 17041527]
[14]
Gaur P, Dixon L, Jones B, Lyall H, Jan W. COVID-19-associated cytotoxic lesions of the corpus callosum. AJNR Am J Neuroradiol 2020; 41(10): 1905-7.
[http://dx.doi.org/10.3174/ajnr.A6713] [PMID: 32819904]
[15]
Goenka AH, Mukund A, Ahuja J, Kumar A. Reversible lesion in the splenium of the corpus callosum in a child with influenza-associated encephalitis–encephalopathy (IAEE). J Clin Neurosci 2010; 17(5): 607-, 678.
[http://dx.doi.org/10.1016/j.jocn.2009.07.093] [PMID: 20358640]
[16]
Ohara H, Shimizu H, Kasamatsu T, et al. Cytotoxic lesions of the corpus callosum after COVID-19 vaccination. Neuroradiology 2022; 64(10): 2085-9.
[http://dx.doi.org/10.1007/s00234-022-03010-y] [PMID: 35809100]

© 2024 Bentham Science Publishers | Privacy Policy